United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by nVerses Capital LLC

nVerses Capital LLC cut its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 88.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 100 shares of the biotechnology company’s stock after selling 800 shares during the period. nVerses Capital LLC’s holdings in United Therapeutics were worth $36,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in UTHR. Vontobel Holding Ltd. lifted its stake in shares of United Therapeutics by 90.4% in the 3rd quarter. Vontobel Holding Ltd. now owns 1,664 shares of the biotechnology company’s stock valued at $596,000 after purchasing an additional 790 shares during the last quarter. Kapitalo Investimentos Ltda raised its holdings in United Therapeutics by 69.4% in the 3rd quarter. Kapitalo Investimentos Ltda now owns 1,470 shares of the biotechnology company’s stock valued at $527,000 after buying an additional 602 shares during the period. Creative Planning lifted its position in United Therapeutics by 8.9% in the third quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock valued at $1,410,000 after buying an additional 322 shares during the last quarter. CHICAGO TRUST Co NA purchased a new position in United Therapeutics during the third quarter worth about $204,000. Finally, Ritholtz Wealth Management increased its position in shares of United Therapeutics by 14.3% during the third quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock valued at $301,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $338.61, for a total value of $1,218,996.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $44,019.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of United Therapeutics stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total transaction of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $833,350.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $338.61, for a total value of $1,218,996.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $44,019.30. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 106,412 shares of company stock worth $36,470,922 over the last three months. Insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on UTHR. Wells Fargo & Company upped their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a report on Tuesday, August 20th. Jefferies Financial Group upped their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $310.00 to $321.00 in a research note on Thursday, July 11th. TD Cowen increased their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday. Finally, UBS Group increased their price target on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $361.33.

United Therapeutics Price Performance

United Therapeutics stock opened at $370.26 on Wednesday. The stock has a market cap of $16.47 billion, a P/E ratio of 17.02, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. The company has a fifty day simple moving average of $351.40 and a 200-day simple moving average of $309.96. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $377.03.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The business had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same period in the prior year, the company posted $5.24 earnings per share. The company’s revenue was up 19.8% compared to the same quarter last year. Equities analysts expect that United Therapeutics Co. will post 24.72 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.